...
首页> 外文期刊>European journal of drug metabolism and pharmacokinetics >Studies on interactions between traditional herbal and Western medicines. IV: lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats.
【24h】

Studies on interactions between traditional herbal and Western medicines. IV: lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats.

机译:传统草药与西药之间相互作用的研究。 IV:在大鼠中,Saiko-ka-ryukotsu-borei-to和卡马西平之间缺乏药代动力学相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The possibility of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to extract powder (TJ-12), a widely used traditional Chinese herbal (Kampo) medicine, and carbamazepine (CBZ), an important anti-epileptic drug, was examined in rats. There were no significant differences in the serum protein binding of CBZ and carbamazepine- 10,11-epoxide (CBZ-E), its active metabolite, at two concentrations (1 and 10 Bg/ml) between twogroups pretreated orally with the vehicle andTJ-12 suspension (1 g/kg/d, p.o.) for 1 week. One-week repeated pretreatment with TJ- 12 (1 g/kg/d) did not influence liver weight, contents of cytochromes P450 and b5 in hepatic microsomes or the formation rate of CBZ-E from CBZ by its microsomes, while pretreatment with phenobarbital (80 mg/kg/d, i.p.) significantly increased these parameters. Neither a single nor 1-week repeated oral pretreatment with TJ-12 (1 g/kg/d) affected the plasma concentration-time profile and any pharmacokinetic parameter of CBZ or CBZ-E after oral administration of CBZ (50 mg/kg). These results indicated that oral co-administration of TJ-12 with CBZ has no effect ofthe pharmacokinetics of CBZ or CBZ-E in rats. Concomitant treatment with TJ- 12 and CBZ appears to be pharmacokinetically safe in humans.
机译:研究了在广泛使用的中草药(Kampo)的Saiko-ka-ryukotsu-borei-提取物粉末(TJ-12)和一种重要的抗癫痫药卡马西平(CBZ)之间的药代动力学相互作用的可能性。大鼠。口服媒介物和TJ-前处理的两组在两种浓度(1和10 Bg / ml)下,CBZ和卡马西平-10,11-环氧化物(CBZ-E)(其活性代谢物)的血清蛋白结合无显着差异。 12悬浮液(1 g / kg / d,口服)1周。 TJ-12(1 g / kg / d)重复一周进行预处理不会影响肝重量,肝微粒体中细胞色素P450和b5的含量或微粒体从CBZ形成CBZ-E的速率,而苯巴比妥预处理(80 mg / kg / d,ip)可以显着提高这些参数。口服CBZ(50 mg / kg)后,单次或重复1周的TJ-12(1 g / kg / d)口服预处理都不会影响血浆浓度-时间曲线和CBZ或CBZ-E的任何药代动力学参数。这些结果表明,TJ-12与CBZ的口服共同给药对大鼠的CBZ或CBZ-E的药代动力学没有影响。 TJ-12和CBZ的伴随治疗似乎在人体中是药物动力学安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号